Scancell appoints healthcare finance veteran as new CFO
29th Aug 2023 14:27
(Sharecast News) - Immunotherapy developer Scancell announced the appointment of Sath Nirmalananthan as its new chief financial officer on Tuesday, effective immediately.
Read moreScancell to present positive recent findings at oncology summit
2nd Jun 2023 13:18
(Sharecast News) - Immunotherapy developer Scancell said on Friday that it is set to present an informative poster at the American Society of Clinical Oncology Meeting (ASCO) 2023 annual meeting in Chicago from 2 to 6 June.
Read moreScancell shares jump on positive cancer vaccine progress
21st Feb 2023 12:14
(Sharecast News) - Immunotherapy developer Scancell announced the completion of the monotherapy dose-finding arm of the phase 1 and 2 'ModiFY' clinical trial on Tuesday.
Read moreScancell licenses Vaccitech IP for its next vaccine candidate
7th Nov 2022 09:29
(Sharecast News) - Scancell has in-licensed 'SNAPvax' technology from clinical-stage biopharmaceutical company Vaccitech, it announced on Monday.
Read moreScancell enrols and doses first patient in latest cancer trial
31st Oct 2022 16:46
(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.
Read moreScancell losses widen on expense of ongoing trials
28th Oct 2022 14:42
(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.
Read moreScancell inks licensing deal with Nasdaq-traded Genmab
25th Oct 2022 14:34
(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.
Read moreScancell presents new, positive data on possible cancer therapies
23rd Sep 2022 13:31
(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.
Read moreScancell developing 'promising' new cancer treatment approach
23rd Jun 2022 12:38
(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.
Read moreScancell updates protocol for UK trial in melanoma patients
15th Jun 2022 15:58
(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.
Read moreScancell opens recruitment for cancer therapy trial
11th Apr 2022 13:10
(Sharecast News) - Immunotherapy developer Scancell announced on Monday that its phase 1 and 2 clinical trial with 'Modi-1' is open for recruitment.
Read moreScancell treats first patient in melanoma tumour trial
19th Nov 2021 13:49
(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell announced on Friday that the enrolment and treatment of the first patient had taken place in its multicentre phase 2 clinical trial of its 'SCIB1' tumour treatment at the Churchill Hospital in Oxford.
Read moreScancell gets MHRA approval for Modi-1 clinical trial
26th Aug 2021 12:38
(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that the UK Medicines and Healthcare products Regulatory Authority (MHRA) has approved the clinical trial application to initiate the first-in-human phase 1 and 2 clinical study of 'Modi-1'.
Read moreScancell chooses needle-free tech for Covid vaccine candidates
17th Aug 2021 15:32
(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell has selected the PharmaJet needle-free injection system to administer its two SARS-CoV-2 vaccine candidates for Covid-19, 'SCOV1' and 'SCOV2', in its 'COVIDITY' phase 1 clinical trial, it announced on Tuesday.
Read moreScancell makes progress with 'Covidity' trial plans
22nd Jun 2021 15:21
(Sharecast News) - Immunotherapy developer Scancell updated the market on 'Covidity' clinical trial plans, and the publication of preclinical data on two vaccine candidates from the research programme.
Read more